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Abstract
The present studies were aimed at investigating the engineering of NPs with protein-conjugated-
surfactant at their surface. In order to increase the immunogenicity of a protein antigen, Brij 78
was functionalized by tresyl chloride and then further reacted with the primary amine of the model
proteins ovalbumin (OVA) or horseradish peroxide (HRP). The reaction yielded Brij 78-OVA and
Brij 78-HRP conjugates which were then used directly to form NP-OVA or NP-HRP using a one-
step warm oil-in-water microemulsion precursor method with emulsifying wax as the oil phase,
and Brij 78 and the Brij 78-OVA or Brij 78-HRP conjugate as surfactants. Similarly, Brij 700 was
conjugated to HIV p24 antigen to yield Brij 700-p24 conjugate. The utility of these NPs for
enhancing the immune responses to protein-based vaccines was evaluated in vivo using ovalbumin
(OVA) as model protein and p24 as a relevant HIV antigen. In separate in vivo studies, female
BALB/c mice were immunized by subcutaneous (s.c.) injection with NP-OVA and NP-p24
formulations along with several control formulations. These results suggested that with multiple
antigens, covalent attachment of the antigen to the NP significantly enhanced antigen-specific
immune responses. This facile covalent conjugation and incorporation method may be utilized to
further incorporate other protein antigens, even multiple antigens, into an enhanced vaccine
delivery system.
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1. Introduction
Recent vaccine development efforts have moved away from traditional vaccines containing
whole organisms and toward safer subunit vaccines containing only the components, such as
protein, peptide or plasmid DNA, necessary to elicit useful immune responses. However,
these new generation vaccines typically have lower immunogenicity and higher cost. Thus,
novel formulations comprising adjuvants or a delivery system are needed to improve
immunogenicity, reduce antigen dose, and reduce cost (Gupta and Siber, 1995; Hagmann,
2000; Yan and Huang, 2007). For a successful peptide or protein antigen delivery system to
effectively induce humoral- and cell-mediated immune responses, an adjuvant or delivery
system is essential since peptides or the protein itself is usually a weak immunogen (Guinn
et al., 2007). However, despite an intensive search for newer and better adjuvants, there are
relatively few approved adjuvants (e.g., Alum, MF59, ASO4) for human use (O'Hagan and
De Gregorio, 2009; O'Hagan et al., 2006; Gabutti et al., 2005; Pichichero, 2008).
Several groups have reported on the use of particles to deliver protein antigens more
effectively to affect the breadth and depth of immune responses (Yoshikawa et al., 2008;
Cui and Huang, 2005; Elamanchili et al., 2007; Patel et al., 2006; Cui and Mumper, 2003;
van den Berg et al., 2010; Aline et al., 2009; Salman et al., 2009; Akagi et al., 2007; Allison
and Gregoriadis, 1974; Alving, 1991). In addition, other groups have shown that the direct
covalent or high-affinity conjugation of protein antigen to particles further enhances immune
responses (Patel et al., 2007b; Sloat et al., 2010a; Sloat et al., 2010b; Dominguez and
Lustgarten, 2010).
To this end, our laboratory has reported on the engineering of solid lipid-based nanoparticles
(NPs) from oil-in-water microemulsion precursors and the use of these NPs for enhancing
immune responses to DNA vaccines (Cui and Mumper, 2002b; Cui and Mumper, 2002c),
cationized β-galactosidase protein (Cui and Mumper, 2002a), and HIV Tat and Gag p24
proteins (Cui et al., 2004; Patel et al., 2006; Patel et al., 2007a). These NPs are
approximately 100 nm in size and have the advantage of being engineered in a single step,
one vessel process. The physical and surface properties of the engineered NPs may be
modified by utilizing surfactants with various charges (i.e., neutral, anionic, or cationic) or
reactive groups (i.e., sulfhydryl, amine, carboxyl). Moreover, the oil phase for the
engineering of these solid lipid NPs is comprised of cetyl alcohol and polysorbate 60; both
of which are found in many pharmaceutical products and are biocompatible (Koziara et al.,
2005). It was hypothesized that increasing the interaction of the antigen for the particles
could lead to increased accumulation of the antigen in the antigen presenting cells (APCs) as
compared to antigen coated on the surface of charged NPs and thus, enable greater
enhancement in immune responses in vivo. Indeed, his-tagged protein antigen was able to
bind NPs decorated with a small amount of accessible nickel on the surface, leading to
enhanced immune responses (Patel et al., 2007b). Apparently, the interaction between
chelated nickel and the short sequence of histidine residues increased the delivery efficiency
of the protein antigen to APCs.
Recently, the hydroxyl group of poly(ethyleneglycol) (PEG)-sterol was used to conjugate a
protein via tresyl chemistry and the protein conjugate was successfully incorporated into a
liposome (Steenpass et al., 2006). It was hypothesized that similar chemistry could be used
to conjugate a protein antigen to NPs engineered with Brij 78 (polyoxyethylene-20 stearyl
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ether) and Brij 700 (polyoxyethylene-100 stearyl ether) as the surfactants. The present
studies were aimed at investigating the engineering of NPs incorporated with protein
conjugated surfactant in NPs. In addition, the utility of these NPs for enhancing the immune
responses to protein-based vaccines were evaluated in vivo using OVA as model protein and
p24 as the relevant HIV antigen.
2. Material and methods
2.1. Materials
Emulsifying wax (E-wax), and aluminum hydroxide were purchased from Spectrum Quality
Products (New Brunswick, NJ). PBS/Tween 20 buffer, ovalbumin (OVA), horseradish
peroxidase (HRP), cetyl trimethylammonium bromide (CTAB), tresyl chloride, and
mannitol were purchased from Sigma Chemical Co. (St. Louis, MO). HIV p24 was
purchased from ARP American Research Products Inc. (MA, USA). Brij 78 and Brij 700
were purchased from Uniqema (New Castle, DE) and Sigma Aldrich (USA), respectively.
Goat anti-mouse IgG and peroxidase-linked species specific F(ab')2 fragment was purchased
from Amersham Pharmacia Biotech (Piscataway, NJ). Tetramethylbenzidine (TMB)
Substrate Kit was purchased from Pierce (Rockford, IL). Complete Freund's adjuvant (CFA)
and incomplete freunds adjuvant (IFA) was purchased from Fisher Scientific (Hampton,
NH).
2.2 Synthesis of tresylated Brij 78 (T-Brij 78) and tresylated Brij 700 (T-Brij 700)
The tresylation of Brij 78 was performed as described previously (Nilsson and Mosbach,
1984). Briefly, Brij 78 (1.15 g, 1 mmol) or Brij 700 (4.67 g, 1 mmol) (Fig 1a) was dissolved
in 10 ml dichloromethane and incubated at 0°C. Tresyl chloride (120 μl, 2 mmol) (Fig 1b)
and 250 μl pyridine was added to the Brij 78 solution drop-wise. The solution was mixed
and the reaction was allowed to continue at room temperature with constant stirring for 18 h
under nitrogen atmosphere, after which the solution was rotary evaporated under reduced
pressure and the precipitate was re-dissolved in 60 ml ethanol with 250 μl HCl. The solution
was kept overnight at -20°C and then the formed precipitate was centrifuged at 2500 rpm at
-5°C. The supernatant was discarded and the pellet was re-suspended in 50 ml ethanol
acidified with 50 μl HCl. The washing steps were repeated until pyridine was removed as
verified by a minimum and constant OD at 255 nm. The solid T-Brij 78 or T-Brij 700 (Fig
1c) was stored at -20°C under nitrogen. Similarly, Brij 700 (4.67 g, 1 mmol) was also
tresylated.
2.3 Preparation of Brij 78-HRP conjugation & preparation and characterization of NP-HRP
Simple standard coupling procedure was established with HRP as a model protein to prepare
Brij 78-HRP conjugate (Steenpass et al., 2006). HRP (100 μl of a 200 μg/ml in 0.1 M
HEPES buffer, pH 8.0) was added to T-Brij 78 (8.0 mg) and allowed to react for 3 h at room
temperature. The reaction mixture was then heated to 55°C and added to 4 mg of melted E-
Wax. The mixture was stirred for 3 min, after which 2 ml de-ionized water was added under
stirring to form the warm oil-in-water microemulsion which was allowed to stir for an
additional 30 min followed by direct cooling to room temperature while stirring to obtain
solid lipid NPs. The engineered (200 μl) NPs were passed down a gravity packed Sepharose
CL4B gel permeation chromatography column (15×80 mm) using PBS buffer, pH 7.4 as the
mobile phase. Fractions (1 ml) were collected and the fractions containing the NPs were
determined by measuring the particle size intensity. The fractions were diluted 200-fold, and
10 μl samples were assayed for HRP enzyme activity using 90 μl TMB as a substrate. The
color development was stopped by addition of 50 μl of 2M H2SO4 and the OD at 450 nm
was read using a Universal Microplate Reader (Bio-Tek Instruments, Inc.).
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2.4 Preparation and characterization of Brij 78-OVA conjugate and engineering of NPs
As described in 2.3 with slight modification, 100 μg of OVA and p24 was reacted with
different weight ratios of Brij 78 and Brij 700, respectively, in 0.1 M HEPES buffer, pH 8.0
at room temperature for 18 h. OVA protein (30 μg total) was subjected to native SDS-Page
gel. The gel was then stained by Coomassie Blue and imaged using a digital camera.
Eight (8) mg of T-Brij 78 was reacted with 1.5 mg OVA in 100 μl 0.1 M HEPES buffer, pH
8.0 at room temperature for 18 h to prepare Brij 78-OVA conjugate. The resulting conjugate
mixture (Fig 1d) was heated to 55-60°C and mixed with 4 mg of melted E-Wax. The
mixture was stirred for 3 min, after which 2 ml de-ionized water was added under stirring to
form the warm oil-in-water microemulsion which was allowed to stir for an additional 30
min followed by direct cooling to room temperature, while stirring to obtain solid NPs. The
un-reacted and unhydrolyzed tresyl group on the surface of the NPs was blocked using 20
mM Tris-HCl buffer, pH 8.0 for 1 h. The 1 ml NP suspension was concentrated to 0.2 ml
using 100 kDa cut-off microcon (Millipore), and then subjected to GPC column as described
in section 2.3. Every fraction was assayed for protein concentration using the BCA method
(Pierce). Nanoparticles (NP-OVA and NP-p24) were engineered and characterized by
measuring their size using the particle sizer at 90° and zeta-potential (surface charge) using a
Malvern Zeta Sizer 2000 (Malvern Instruments, Southborough, MA).
2.5 Engineering of cationic NPs and coating the OVA
Cationic NPs from oil-in-water microemulsion precursors were engineered as previously
described with slight modifications (Patel et al., 2007a). Briefly, 2 mg of E-Wax and 3.5 mg
of Brij 78 was melted and mixed at ∼65°C. De-ionized water (980 μl) was added to the
melted wax and surfactant while stirring to form an opaque suspension. Finally, 20 μl of
cetyl trimethylammonium bromide (CTAB) (50 mM) was added to form clear
microemulsions at 60-65°C. The microemulsions were cooled to room temperature while
stirring to obtain NPs (2 mg/ml). The final concentration of components in the NP
suspension was E-Wax (2 mg/ml), Brij 78 (3 mM), and SDS (1 mM). OVA protein was
added to NPs (1000 μg/ml) in 5% (v/v) mannitol at a ratio of 10:1 (weight ratio of E-Wax:
protein). The suspension was gently vortexed and placed on a horizontal shaker at room
temperature for a minimum of 30 min to allow for coating. These coated NPs (NP/OVA)
were diluted appropriately in de-ionized water for particle size and zeta potential
measurements.
2.6 Mouse immunization study
Female BALB/c mice (8–10 weeks old) were immunized subcutaneously with 150 μl of the
formulations. Mice (n = 8/group) were dosed on day 0 and 14 with NP-OVA, NP/OVA, Brij
78-OVA and OVA adjuvanted with Alum (OVA+Alum). The doses of OVA and Alum in
every group were kept as 5 and 100 μg, respectively, per mouse. As a positive control, mice
were immunized on day 0 with 5 μg of OVA adjuvanted with complete Freund's adjuvant
(CFA) followed by a boost with 5 μg OVA adjuvanted with incomplete Freund's adjuvant
(IFA) on day 14. On day 28, mice were bled by cardiac puncture and sera were separated.
All sera collected were stored at −20°C for further characterization.
2.7 Determination of anti-OVA and anti-p24 antibody titers
OVA specific serum IgG, IgG1 and IgG2a antibody titers were determined using an ELISA
as described previously (Patel et al., 2007a). Briefly, 96-well plates (Costar) were coated
with 100 μl of OVA (10 μg/ml in 0.01 M carbonate buffer, pH 9.6) overnight at 4°C. The
plates were blocked for 1 h at 37°C with 200 μl of 2% BSA prepared in PBS/Tween 20. The
plates were then incubated with 100 μl per well of mouse serum diluted appropriately in 2%
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BSA/PBS/Tween 20 for 2 h at 37°C. The plates were washed with PBS/Tween 20 and
incubated with 100 μl/well sheep-anti-mouse IgG HRP (1:5000 in 2% BSA/PBS/Tween 20)
for 1 h at 37°C. For IgG1 and IgG2a determination, the plates were similarly incubated with
goat anti-mouse IgG1-HRP or goat anti-mouse IgG2a-HRP diluted 1:5000 (2% BSA/PBS/
Tween 20). After washing the plates with PBS/Tween 20, plates were developed by adding
80 μl of TMB substrate and incubated for 10 min at RT. The color development was stopped
by the addition of 50 μl of 2M H2SO4 and the OD at 450 nm was read using a Bio-Tek
Synergy 2 Microplate Reader (Bio-Tek Instruments, Inc.). The endpoint titer was defined as
the highest reciprocal dilution of sera yielding an OD450 value at least 3 × background
obtained using samples taken from naïve mice. The same procedure was followed for the
determination of p24 specific serum IgG antibody titers, but with slight modifications.
2.8 Statistical analysis
Statistical analysis was performed using either one-way analysis of variances (ANOVA)
followed by pair-wise comparisons using Tukey's multiple comparison test using GraphPad
Prism software or Students t-test. Data were considered statistically significant when p value
was less than 0.05.
3. Results and Discussion
3.1 Incorporation of HRP into NPs
The surfactant-protein conjugate approach was utilized to attach proteins to NPs. The more
conventional method of attaching HRP directly onto pre-made NPs was not successful since
it required functionalization of hydroxyl group of Brij 78 on the surface of NPs via tresyl
chemistry. When the HRP was reacted with the engineered NPs; HRP enzymatic activity
was not detected in the NP fractions, suggesting no HRP conjugation to NPs (data not
shown). There were two possible reasons; 1) hydrolysis of tresyl groups on Brij 78 during
the process of NP engineering, leading to de-functionalization of the NPs, and 2) steric
hindrance of the NPs and protein, both of which prevented the amine group of the protein
from reacting with the Brij 78 on the surface of the NPs. To avoid these problems, Brij 78
was first covalently attached to HRP at pH 8.0 resulting in the stable synthesis of the Brij
78-HRP conjugate (Fig 1d), which was then incorporated into the solid lipid NPs which
were successfully engineered via the oil-in-water microemulsion precursor method. These
engineered NPs were then fractionated using a GPC column, followed by NP
characterization and utilizing an enzymatic assay to quantify retained HRP activity. Particle
intensity indicated that NPs were distributed in fraction 4 and 5, which were associated with
HRP activity when Brij 78 was reacted with HRP. A control of HRP coated on non-tresyl
modified Brij 78 NPs showed no HRP activity in the NP fraction 4 and 5 (Fig 2), proving
that little or no non-specific binding of HRP to the NPs made with non-tresylated Brij 78.
Fig 2 also indicates about 30% of the enzymatic activity was associated with NPs made with
Brij 78. These data indicate HRP model protein was able to be conjugated to Brij 78 and
subsequently incorporated into NPs as depicted in Fig 1.
3.2 Conjugation of OVA to Brij 78 and Incorporation of Brij 78-OVA to NPs
The retention of significant HRP enzymatic activity on the NPs suggested that the
tresylation method could be used to formulate protein antigen coupled NPs. However, it did
not provide any quantitative information about the amount of protein attached to the NPs.
Therefore, the widely used model antigen OVA was utilized to study and optimize the
conjugation of OVA to Brij 78, with subsequent incorporation of the conjugate into NPs.
Different weight ratios of OVA to Brij 78 were designed to optimize the conjugation
conditions. The moderate basic condition of pH 8.0 which significantly reduced the
hydrolysis of tresyl groups and at the same time prevented the protonation of primary
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amines of protein, resulted in high overall conjugation efficiency. The reaction mixtures
were then subjected to native SDS-PAGE (Fig 3a).
The position of a protein on a native gel is influenced not only by the size of the protein, but
also by its charge and aggregation status. The Brij 78 portion of the synthesized protein
conjugate contains a hydrophobic stearyl moiety which may lead to aggregation of the
protein to form oligomers or multimers. Fig 3a shows that as the amount of T-Brij 78 to
OVA was increased, the amount of free OVA gradually decreased and the amount of Brij
78-OVA conjugate was increased. There was no significant difference in staining of SDS-
PAGE bands between the weight ratios of 10:1 and 5:1 T-Brij 78:OVA conjugate suggesting
the maximal conjugation efficiency was achieved at weight ratio of about 5:1. Therefore,
this weight ratio was used in subsequent engineered NPs. According to the molecular
weights of OVA and Brij 78, there was about a 160-fold molar excess of Brij 78 in the
reaction mixture. Regardless, the unreacted Brij 78 was not removed, but directly utilized
together with Brij 78-OVA conjugate and E-Wax to form the oil-in-water microemulsion
precursor which was then used to form solid NPs since the total Brij 78 (unreacted Brij 78
and the Brij 78-OVA) was precisely the amount of Brij 78 required to engineer the E-Wax
NPs. Thus, the solid NPs were formed using a combination of Brij 78 and T-Brij 78 that was
equivalent to the amount of Brij 78 alone required to form placebo or blank NPs. The
formed NPs were fractionalized using a GPC column. The total protein concentrations in the
fractions were assayed by the BCA method and are summarized in Fig 3b. Similar to the
results in Fig 2, the OVA protein was successfully attached to NPs as evidenced by fractions
4 and 5. The NP-associated OVA was around 30% of the total protein input in the initial
conjugation reaction as determined by the protein assay. NPs were characterized by both
particle size and zeta potential and the data are summarized in Table 1.
The NP-OVA had similar particle size and PI values compared to blank NPs formed by E-
Wax and Brij 78 alone, but had a more negative zeta potential due to negative charged OVA
protein on the surface of NPs. However, both NP-OVA and blank NPs had smaller sizes
than NP/OVA complex. The NP-OVA formulation, filtered through a 0.22 μm filter, was
stable for at least one week at 4°C. It should be noted that no formal stability study of the
formulations was performed.
3.3. Immune response to NP-OVA formulation
In vivo studies in BALB/c mice were carried out to investigate the use of NP-OVA as a
potential delivery system to enhance the immune responses to OVA. Mice were immunized
with NP-OVA, cationic NP/OVA complex (NP/OVA), OVA adjuvanted with Alum (Alum
+OVA), Brij 78-OVA conjugate on day 0 and 14. Our previous results showed that at a
neutral pH, negatively charged OVA efficiently bound to cationic NPs made by the addition
of CTAB as a co-surfactant and formed a stable NP/OVA complex (Patel et al., 2007a). As a
positive control, mice were immunized with OVA adjuvanted with CFA (OVA+CFA) using
the same immunization protocol. The OVA antigen dose among all the groups was 5 μg per
mouse. Sera collected from mice were analyzed for total OVA-specific IgG at 14 days post
second immunization. As expected, animals immunized with OVA adjuvanted with CFA
+IFA resulted in the highest total IgG titers among all the groups. More importantly, 5-10
fold greater titers were observed using NP-OVA compared to Alum+OVA, or Brij 78-OVA,
or NP/OVA (Fig 4a). The Brij 78-OVA conjugate control had similar antibody response
with Alum+OVA suggesting the protein conjugation itself increased the immunogenicity of
the OVA as presented in Fig 4a. Our previous studies reported anionic NP/Tat complex
enhanced humoral immune responses compared with Tat adjuvanted with Alum (Cui et al.,
2004; Patel et al., 2006); however, current studies indicated no difference between the
cationic NP/OVA complex and Alum+OVA. It has been shown that cationic surfactants are
more toxic than anionic and neutral surfactants at the same concentration (Lewis, 1990).
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Recently, it was reported that high doses of cationic liposome induced apoptosis of dendritic
cells leads to compromised immune responses (Yan et al., 2008). Therefore, the cationic
NP-induced dendritic cell apoptosis may explain the weaker adjuvant activity of cationic
NPs compared to the anionic NPs. However, the toxicity profiles of the cationic NPs and
anionic NPs require further systematic investigation. Overall, these data support that protein
covalently bound to NPs was superior to Alum and NP/OVA complexes in enhancing
humoral immune responses to model antigen OVA.
The serum isotype levels, IgG1 versus IgG2a, were measured to assess the type of immune
response generated (i.e., Th2 or Th1 respectively). During an immune response, the release
of Th1 or Th2 cytokines will affect the production of these antibodies. BALB/c mice bias
the immune response towards a Th2 profile (Guler et al., 1997; Bix et al., 1998) generating
relatively higher levels of antibodies of IgG1 isotype; however, in the presence of Th1 type
immune responses, the cells produce Th1 cytokines which cause a switch in the isotype
produced to IgG2a. The isotype analysis in these studies revealed that the NP-OVA resulted
in the superior IgG1 (Fig 4b) and IgG2a (Fig 4b) levels compared to NP/OVA, Alum+OVA
and Brij 78-OVA, suggesting the enhanced and balanced Th1 and Th2 immune responses
can be generated by NP-OVA formulation.
Human immunodeficiency virus type-1 (HIV-1) capsid protein p24 is the main component
of tubular core in the mature HIV particle (Marechal et al., 1998). Studies have found p24 to
be relatively conserved among HIV subtypes. Decrease in the level of antibodies to p24 and
p24 antigen has been considered to be one of the most useful prognostic markers in HIV
infected individuals (Bollinger Jr et al., 1992). Therefore, most assays have been developed
to detect HIV antibodies which use p24 as an integral component in addition to envelope
glycoproteins. Inhibition of capsid formation can be an effective prophylactic or therapeutic
strategy (Tang et al., 2003). Thus, p24 is a rationale target antigen.
Therefore, to assess this proof of concept, Brij 700-p24 antigen conjugate was prepared, as
described above, and coated onto the NPs and total IgG was assessed (Fig. 5). The total IgG
for NP-p24 was found to be increased as compared to Brij 700-p24 conjugate and p24
adjuvanted with Alum. Brij 700 was utilized in later studies using p24 since other studies
have shown that the longer chain poloxyethylene chain improves both the conjugation
efficiency and loading onto nanoparticles due to reduced steric hindrance near the surface of
the nanoparticles (unpublished results). These data demonstrate the potential applications of
these NPs for vaccine delivery and warrant further investigation of these systems for
enhancing immune responses with HIV protein antigen based vaccines.
4. Conclusions
Covalent conjugation of protein antigen to NPs through tresyl chemistry is a novel approach
to increase the immunogenicity of the poorly immunogenic proteins. This facile covalent
conjugation and incorporation method may be utilized to incorporate other peptide and
protein antigens, even multiple antigens, into an enhanced vaccine delivery system.
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Synthesis and Engineering Scheme for NP-protein formulation. Functionalization of Brij 78
(X=20) & Brij 700 (X=100) (a) by tresyl chloride (b). The resulting T-Brij conjugate (c) was
reacted with protein to form Brij 78-protein or Brij 700-protein conjugate (d). The NP-
protein (e) was engineered via warm oil-in-water microemulsion precursors using E-wax as
oil phase and the synthesize protein conjugate (d) as the surfactant.
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HRP enzymatic activity associated with NPs made using Brij 78 (■) and T-Brij 78 (□).
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(A) Conjugation of OVA protein to T-Brij 78: Different weight ratios of T-Brij 78:OVA
were used to conjugate OVA to T-Brij 78, followed by native PAGE gel separation. Thirty
microgram of OVA was loaded onto the gel and stained by Coomassie Blue and imaged
using a digital camera. (B) The GPC purification profile for particle intensity and protein
concentration of OVA associated with NPs.
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Fig 4. OVA specific humoral responses after immunization with NP-OVA formulations
Mice were immunized with 5 μg of OVA covalently bound to NPs (50 μg) (NP-OVA),
coated on cationic NPs (50 μg) (NP/OVA), adjuvanted with Alum (50 μg) (Alum+OVA),
Brij 78-OVA conjugate or adjuvanted with CFA on day 0 and day 14. Total anti-OVA
serum IgG levels (A) and IgG1 (B) were measured on day 28. The data for each group
represents the mean ± SD (n=8). ** p <0.01 compared to NP/OVA, Alum+OVA and Brij
78-OVA. Serum IgG2a levels were measured on day 28 by ELISA at a 1:100 serum
dilution. The data for each group represents the mean ± SD (n=6-8). * p<0.05 compared to
NP/OVA, Alum+OVA and Brij 78-OVA.
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Fig 5. p24 specific humoral responses after immunization with NP-p24 formulations
Mice were immunized with 5 μg of p24 coated to NPs (50 μg) (NP-p24), adjuvanted with
Alum (100 μg) (Alum+p24), Brij 700-p24 conjugate on day 0 and day 7. Total anti-p24
serum IgG levels were measured on day 25 by ELISA at a 1:1000, 1:5000, and 1:10000
serum dilutions. *p<0.05 compared to Alum+p24 and Brij 700-p24. The data for each group
represents the mean ± SD (n=3).
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Table 1









NP/OVAa 111.2 ± 13.2 0.199 ± 0.069 +25.6 ± 4.4
NP-OVAb 81.8 ± 1.0 0.270 ± 0.065 -19.3 ± 0.7
NPsc 82.8 ± 3.5 0.120 ± 0.099 -3.2 ± 0.3
a
Cationic NPs engineered with E-wax, Brij 78 and 1 mM CTAB were coated with OVA at a final weight ratio of 10:1 (w/w) (E-Wax:OVA)
b
Purified NPs conjugated with OVA.
a,b
OVA concentration was 0.1 mg/ml formulation of NPs;
c
Blank NPs made with E-wax and Brij 78
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